CTKB / Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to Decline

Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get more_horizontal

FREMONT, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced more_horizontal

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - more_horizontal

FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced more_horizontal

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Paul Goodson - Head Investor Relat more_horizontal

Cytek focuses on cell analysis primarily for research purposes. The company joined the S&P SmallCap 600 Index last month. more_horizontal

Cytek Biosciences, Inc. (CTKB) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earning more_horizontal

Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev more_horizontal